HOBOKEN, N.J.--(BUSINESS WIRE)--Genesis Research today announced data from a study it conducted comparing total costs of care over time in multiple myeloma patients receiving either lenalidomide or bortezomib-based regimens, presented at the 57th American Society of Hematology Annual Meeting. Results of the study show that initial high monthly total costs declined over time until returning to near initial levels upon relapse and the initiation of later lines of treatment, leading to cost savings for patients who are treated with therapy that extends time to relapse.
In the study, a retrospective analysis was performed using a large U.S. medical and pharmacy claims database, covering more than 25 million commercial and Medicare lives annually. The analysis focused on patients who received lenalidomide or bortezomib-based first line therapy and had evidence of the initiation of a subsequent line of therapy.
A total of 1,181 patients with newly-diagnosed multiple myeloma were included in the analysis with 444 having received lenalidomide-based therapy and 737 having received bortezomib-based therapy in the first-line. Monthly total direct medical plus pharmacy costs for all patients were in excess of $12,000 at initiation. These costs declined quarterly in both arms until the median time to next therapy was reached (20 months for bortezomib; 37 months for lenalidomide). As increasing numbers of patients in each arm progressed and initiated subsequent therapy, increased costs began to offset continued cost declines for patients still on first-line therapy.
Over the total 54 month follow-up period, total monthly costs averaged $8,749 for patients initiated with lenalidomide compared to $10,728 for patients initiated with bortezomib. This resulted in more than $100,000 lower costs per patient in the lenalidomide arm.
“The results of this analysis clearly show that delaying disease progression reduces total cost of treatment over time, as initiation of subsequent therapies is associated with a sharp increase in costs,” said Steven Arikian, M.D., Managing Director of Genesis Research and the lead investigator of the study. “As medical costs were more than half the total in each arm of this analysis, utilizing innovative therapies that extend remissions provided patients the opportunity to avoid costly procedures and kept total costs lower for a longer period of time.”
ABOUT GENESIS RESEARCH
Genesis Research is an international healthcare research consultancy providing evidence development and communication services for Life Sciences groups, with offices located in Hoboken, New Jersey and London, England.